We are upgrading the operating system for cancer precision medicine.

Information is everywhere, but understanding is still rare. We aim to deliver not just more data, but differentiated insights about patients and diseases in order to drive better outcomes. The core of our approach is a platform for CRISPR-powered ‘personalized functional genomics’, which allows efficient, scalable, and individualized assessment of target vulnerabilities directly in clinical samples. For today’s patients, this can identify therapeutic opportunities that aren’t accessible in any other way. For tomorrow’s patients, this powers development of new therapies against critical disease drivers that often hide in plain sight.

Our Platform

image description

A first-in-class platform for primary cell CRISPR profiling

image description

Personalized medicine based on cutting edge functional genomics

image description

Highly differentiated target identification and validation, accessing novel targets for drug development

Our Investors

  • A16z logo
  • Section32 logo
  • Casdin logo
  • Alexandra logo